医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

製薬

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Alexion Announces Successful Phase 3 PREVENT Study in Patients with Neuromyelitis Optica Spectrum

2018年09月24日

0

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Approval in Japan for Frontline Hodgkin Lymphoma Seattle Genetics Announces ADCETRIS

2018年09月21日

0

MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil

MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: for Contezolid and Contezolid Acefosamil MicuRx Announces Receipt of FDA's QIDP

2018年09月21日

0

SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

バイオテクノロジーヘルスケア幹細胞製薬　 TimeLine: Companies for Joint Research on the Appropriate Notice Regarding an Equity and Business Alliance Stable Distribution of Regenerative Cell Medicine

2018年09月21日

0

SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623

バイオテクノロジーヘルスケア幹細胞臨床試験製薬　 TimeLine: and Business Alliance Between Five Companies for and Stable Distribution of Regenerative Cell Appropriate Use Medicine SB623 Supplementary Information to the Notice Regarding

2018年09月21日

0

盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定

盟科医药宣布Contezolid和Contezolid acefosamil获得美国FDA的QIDP和Fast Track认定

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: 盟科医药宣布Contezolid和

2018年09月21日

0

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

ヘルスケア感染症腫瘍学臨床試験製薬　 TimeLine: patients with advanced BRAF-mutant melanoma Pierre Fabre Receives EU Approval for BRAFTOVI

2018年09月21日

0

Walgreens Boots Alliance Announces Launch of Flagship Store on Alibaba Group’s Tmall Global Platform to Sell Own Beauty Brands to Chinese Consumers

Walgreens Boots Alliance Announces Launch of Flagship Store on Alibaba Group’s Tmall Global Platform to Sell Own Beauty Brands to Chinese Consumers

ヘルスケアヘルス一般製薬　 TimeLine: Alibaba Group's Tmall Global Platform to Sell Chinese Consumers Walgreens Boots Alliance Announces Launch

2018年09月20日

0

ＰＨＣホールディングス株式会社：患者さんとのコミュニケーション充実と薬歴作成業務の効率化を目指した薬剤師向け服薬指導用ソフトウェア「薬歴アシスト」を販売開始

ＰＨＣホールディングス株式会社：患者さんとのコミュニケーション充実と薬歴作成業務の効率化を目指した薬剤師向け服薬指導用ソフトウェア「薬歴アシスト」を販売開始

ヘルスケア製薬　 TimeLine: PHCホールディングス株式会社コミュニケーション充実患者歴アシスト薬剤師向け服薬指導用ソフトウェア

2018年09月20日

0

Immunomic Therapeutics将在2018年中国医药创新与投资大会上发言

Immunomic Therapeutics将在2018年中国医药创新与投资大会上发言

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Immunomic Therapeutics将在2018年中国医

2018年09月19日

0